[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:transthyretin-mediated-amyloid-cardiomyopathy":3},{"name":4,"total":5,"trials":6,"biomarkers":15,"states":16},"Transthyretin-Mediated Amyloid Cardiomyopathy",1,[7],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05667493","An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)",[11],"Phase 3","ENROLLING_BY_INVITATION","2026-08-03T02:17:43.428438Z","2026-06-16T05:54:08.084506Z",[],[]]